Capricor Therapeutics (CAPR) Interest & Investment Income (2010 - 2026)
Capricor Therapeutics' (CAPR) quarterly Interest & Investment Income came in at -$536881.0 in Q1 2026, down 173.59% year-on-year from $729542.0 in Q1 2025, and up 4.29% quarter-over-quarter from -$560968.0 in Q4 2025.
Capricor Therapeutics (CAPR) Interest & Investment Income (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Interest & Investment Income history runs 17 years deep, the most recent figure standing at -$536881.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 173.59% year-over-year to -$536881.0 in Q1 2026; TTM through Mar 2026 was -$2.1 million, a 220.34% decrease from a year earlier, with the FY2025 full-year figure at -$743801.0, down 133.76% from the prior year.
- Interest & Investment Income rose to -$536881.0 in Q1 2026 per CAPR's latest filing, from -$560968.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $729542.0 in Q1 2025 and bottomed at -$560968.0 in Q4 2025.
- The 5-year median for Interest & Investment Income is $22830.0 (2022), against an average of $21703.6.
- Across the five-year window, Interest & Investment Income surged 2275.49% in 2022 and plunged 280.28% in 2024, its largest moves.
- Year by year, Interest & Investment Income stood at $379699.0 in 2022, then slumped by 67.71% to $122605.0 in 2023, then surged by 459.99% to $686572.0 in 2024, then tumbled by 181.71% to -$560968.0 in 2025, then advanced by 4.29% to -$536881.0 in 2026.
- Per Business Quant, the three latest CAPR Interest & Investment Income figures stand at -$536881.0 (Q1 2026), -$560968.0 (Q4 2025), and -$543452.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Capricor Therapeutics | 404.05 Mn | 404.05 Mn | - | -536,881.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -536,881.00 |
| Dec 31, 2025 | -560,968.00 |
| Sep 30, 2025 | -543,452.00 |
| Jun 30, 2025 | -424,353.00 |
| Mar 31, 2025 | 729,542.00 |
| Dec 31, 2024 | 686,572.00 |
| Sep 30, 2024 | 453,152.00 |
| Jun 30, 2024 | -152,714.00 |
| Mar 31, 2024 | 71,888.00 |
| Dec 31, 2023 | 122,605.00 |
| Sep 30, 2023 | -66,485.00 |
| Jun 30, 2023 | 84,707.00 |
| Mar 31, 2023 | -10,258.00 |
| Dec 31, 2022 | 379,699.00 |
| Sep 30, 2022 | 99,637.00 |
| Jun 30, 2022 | 22,830.00 |
| Mar 31, 2022 | 13,440.00 |
| Dec 31, 2021 | 15,984.00 |
| Sep 30, 2021 | 15,570.00 |
| Jun 30, 2021 | 16,741.00 |